Valuation: MetaVia Inc.

Market Cap 7.69M 6.74M 6.22M 5.81M 10.93M 728M 11.18M 74.85M 28.9M 359M 28.9M 28.26M 1.25B P/E 2026 *
-0.6x
P/E 2027 * -0.62x
Enterprise Value 7.69M 6.74M 6.22M 5.81M 10.93M 728M 11.18M 74.85M 28.9M 359M 28.9M 28.26M 1.25B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
63.5%
Yield 2026 *
-
Yield 2027 * -
1 day+4.20%
1 week-5.10%
Current month-47.54%
1 month-47.54%
3 months+22.13%
6 months-83.44%
Current year-82.30%
1 week 1.41
Extreme 1.41
1.66
1 month 1.41
Extreme 1.41
2.96
Current year 0.97
Extreme 0.9661
9.61
1 year 0.97
Extreme 0.9661
19.03
3 years 0.97
Extreme 0.9661
74.25
5 years 0.97
Extreme 0.9661
14,863.21
10 years 0.97
Extreme 0.9661
79,200.08
Manager TitleAgeSince
Chief Executive Officer 50 2023-08-10
Director of Finance/CFO 68 2023-10-26
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 79 2022-01-26
Chairman 68 2022-01-13
Director/Board Member 60 2023-05-10
Date Insider Type Main position Quantity % Market Cap.
06-07Free

Director

17,186 0.3328%
06-07Free

Director

17,186 0.3328%
06-07Free

Chairman

17,186 0.3328%
Change 5-day change 1-year change 3-year change Capi.($)
+4.20%-5.10%-78.50%-96.13% 7.39M
+0.13%-1.33%+63.86%+121.93% 55.63B
+6.76%+18.10%+91.66%+104.09% 52.25B
+3.33%+4.51%-11.68%-11.91% 23.07B
+1.32%+6.22%+5.28%+415.45% 22.41B
+0.97%+3.81%+31.23%-32.21% 15.94B
-0.89%+5.71%+24.30%+186.29% 13.77B
+9.96%+15.98%+157.65%+310.89% 13.47B
+2.85%+2.81%+75.32%+139.44% 11.82B
+6.17%+10.22%+163.15%+166.44% 11.16B
Average +3.48%+5.62%+52.23%+130.43% 21.95B
Weighted average by Cap. +3.22%+7.52%+63.12%+141.21%

Financials

2026 *2027 *
Net sales - -
Net income -18.05M -15.8M -14.59M -13.62M -25.65M -1.71B -26.23M -176M -67.78M -842M -67.78M -66.29M -2.92B -27.58M -24.15M -22.3M -20.82M -39.2M -2.61B -40.09M -268M -104M -1.29B -104M -101M -4.47B
Net Debt - -
Logo MetaVia Inc.
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.
Employees
8
Date Price Change Volume
26-06-29 US$1.490 +4.20% 91,613
26-06-26 US$1.430 -6.54% 99,662
26-06-25 US$1.530 -1.92% 337,742
26-06-24 US$1.560 +1.30% 85,155
26-06-23 US$1.540 -1.91% 517,652
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.490USD
Average target price
19.33USD
Spread / Average Target
+1,197.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MTVA Stock